Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Parnell Pharmaceuticals (PARNF)
OTHER OTC:PARNF
Holding PARNF?
Track your performance easily
PARNF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.02
Volume500.00
Average Volume (3M)N/A
Market Cap
$18.00
Enterprise Value$26.79M
Total Cash (Recent Filing)AU$4.40M
Total Debt (Recent Filing)AU$45.04M
Price to Earnings (P/E)―
Beta64.55
Next Earnings
Dec 23, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation18.48
R-Squared0.02
Alpha4.25
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
―
Mutual Funds
1.51% Other Institutional Investors
98.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
PARNF FAQ
What was Parnell Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Parnell Pharmaceuticals’s market cap?
Currently, no data Available
When is Parnell Pharmaceuticals’s upcoming earnings report date?
Parnell Pharmaceuticals’s upcoming earnings report date is Dec 23, 2019 which is 1784 days ago.
How were Parnell Pharmaceuticals’s earnings last quarter?
Parnell Pharmaceuticals released its earnings results on Oct 14, 2019. The company reported -$0.059 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.059.
Is Parnell Pharmaceuticals overvalued?
According to Wall Street analysts Parnell Pharmaceuticals’s price is currently Overvalued.
Does Parnell Pharmaceuticals pay dividends?
Parnell Pharmaceuticals does not currently pay dividends.
What is Parnell Pharmaceuticals’s EPS estimate?
Parnell Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Parnell Pharmaceuticals have?
Parnell Pharmaceuticals has 18,146,000 shares outstanding.
What happened to Parnell Pharmaceuticals’s price movement after its last earnings report?
Parnell Pharmaceuticals reported an EPS of -$0.059 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Parnell Pharmaceuticals?
Currently, no hedge funds are holding shares in PARNF
---
Company Description
Parnell Pharmaceuticals
Parnell Pharmaceuticals Holdings Ltd. is a veterinary pharmaceutical company, which engages in the development, manufacture, and commercializing animal health solutions. It operates through the following segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World, and Manufacturing Operations. The Companion Animal segment sells osteoarthritis suite of products Zydax, Glyde, and Tergive for canine, and equine species. The Production Animal-U.S. segment includes reproductive hormone portfolio across production animals. The Production Animal-Rest of World segment provides reproductive hormone products outside of the U.S. The Manufacturing Operations segment involves in sterile manufacturing and release of pharmaceutical products. The company was founded on June 25, 2009 and is headquartered in Sydney, Australia.
---
---